Spravato (esketamine) is prescribed for adults to treat: major depressive disorder (MDD), also called depression, with suicidal thoughts or actions treatment-resistant depression For MDD ...

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one ...

Discover recent clinical trial failures in depression and explore potential pathways for advancing antidepressant drug ...

In 2019, esketamine (Spravato), derived from ketamine, was approved by the FDA as a nasal spray for treatment-resistant depression. While ketamine therapy has shown promising results, its use ...

So SPRAVATO is indicated for treatment resistant depression. It is esketamine. It's a single enantiomer of ketamine. It's an intranasally administered compound. It was approved in 2019 for ...

Elon Musk discussed his use of ketamine for depression during an interview, claiming it helps him combat negative mental ...

Tesla boss Elon Musk seems to be on a mission to conquer the world, and even Mars. But his odd-hour rants, alleged Nazi ...

Up to 40% of people who suffer from depression are unable to find any relief for their condition. But now, Blessing ...

Cybin (CYBN) stock earns Guggenheim's Buy rating with a $35 target, as the firm cites blockbuster potential for CYB003 in line with J&J's (JNJ) Spravato. Read more here.

Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya ...